A look at the revised prospectus indicates that I'm wrong about other partners income, the 36 month window is applied to Novartis alone. While this is probably where the money would come from, XON could certainly benefit from other income from other GNVC partners.
It appears so, but it's hard to believe that a row boat (GNVC) can affect a battleship (XON) that has a market cap around 150 times greater!
<< To some degree I believe this buyout is creating weakness in XON's share price as investors can purchase GNVC at barely over .297 of XON and know they may see $1 or more a share if the hearing drug moves forward in the next 3 years. >>
News 
Market Data 
Discover 
AI
